SoftOx Solutions AS (OSL:SOFTX)

Market Cap	260.52M +187.8%
Revenue (ttm)	15.58M +96.9%
Net Income	-10.81M
EPS	-0.00
Shares Out	2.50B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,551,720
Average Volume	98,355,960
Open	0.1138
Previous Close	0.1134
Day's Range	0.1030 - 0.1148
52-Week Range	0.0490 - 0.1745
Beta	0.99
RSI	50.37
Earnings Date	May 27, 2026

About SoftOx Solutions AS

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that develops antimicrobials products for infection prevention and treatment in Norway. The company develops SoftOx Inhalation Solution, an inhalation solution that is phase II clinical trial for the treatment of ventilator associated pneumonia and other airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. SoftOx Solutions AS was founded in 2012 and is headquartered in Fornebu, Norwa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 2
• Stock Exchange: Oslo Børs
• Ticker Symbol: SOFTX

Financial Performance

In 2025, SoftOx Solutions AS's revenue was 15.58 million, an increase of 96.92% compared to the previous year's 7.91 million. Losses were -10.81 million, -74.82% less than in 2024.